



IPW

# CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers Date: March 22, 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Supplemental Information Disclosure Statement</b>  <b>Address to:</b> <b>Commissioner of Patents</b> <b>PO Box 1450</b> <b>Alexandria, VA 22313-1450</b>	<b>First Named Inventor</b>	<b>James Patrick Dunn</b>
	<b>Application Number</b>	<b>10/824,731</b>
	<b>Filing Date</b>	<b>April 15, 2004</b>
	<b>Group Art Unit</b>	<b>1614</b>
	<b>Examiner</b>	<b>Not yet assigned</b>
	<b>Attorney Docket No.</b>	<b>R0163B-REG</b>
	<b>Title</b>	<b>SUBSTITUTED QUINAZOLINE COMPOUNDS USEFUL AS P38 KINASE INHIBITORS</b>

Sir:

### Transmittal Letter for Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner an International Search Report, dated December 22, 2004 for the PCT application that is a counterpart of the subject application. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application.

- [X] Attached with this Transmittal Letter are:
- (a) A copy of the PCT International Search Report;
  - (b) Form 1449, "Information Disclosure Statement By Applicants," with copies of C1-C 5;
  - (c) Return postcard.
- [X] The Information Disclosure Statement is being submitted before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**
- [X] Additionally, the undersigned hereby certifies under 37 C.F.R. 1.97(e)(1) that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office on a counterpart foreign application not more than three (3) months prior to the filing of the Information Disclosure Statement. **Therefore, no fee is due.**

- [X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Grant D. Green', written over a horizontal line.

Grant D. Green  
Reg. No. 31,259  
Attorney for Applicants

Roche Palo Alto  
Patent Law Dept. M/S A2-250  
3431 Hillview Avenue  
Palo Alto, CA 94304  
Direct Phone (650) 855-5311

Date: March 22, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTS**

(use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/824,731
Filing Date	April 15, 2004
First Named Inventor	James Patrick Dunn
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	R0163B-REG

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	C1	WO 92/07844 A1	14-May-1992	Pfizer Inc., Groton, CT		
	C2	EP 1 052 254 A1	15-Nov-2000	Eisai Co., Ltd. Tokyo, JP		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C3	WANDEL, et al, "P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies <sup>1</sup> ", <b>Cancer Research, August 15, 1999, pp 3944-3948, Vol 59:16</b>	
	C4	WEBB, et al., "Quinazolines as Adenosine Receptor Antagonists: SAR and Selectivity for A <sub>2B</sub> Receptors", <b>Bioorganic &amp; Medicinal Chemistry, (2003), pp 77-85, Vol 11</b>	
	C5	HESS, et al., "Antihypertensive 2-Amino-4(3H)-quinazolines", <b>Journal of Medicinal Chemistry, (1968), pp 130-136, Vol 11:1</b>	

Examiner  
SignatureDate  
Considered

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Doc. #128569